JP2025513827A5 - - Google Patents
Info
- Publication number
- JP2025513827A5 JP2025513827A5 JP2024560232A JP2024560232A JP2025513827A5 JP 2025513827 A5 JP2025513827 A5 JP 2025513827A5 JP 2024560232 A JP2024560232 A JP 2024560232A JP 2024560232 A JP2024560232 A JP 2024560232A JP 2025513827 A5 JP2025513827 A5 JP 2025513827A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid construct
- construct according
- acid sequence
- srrna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17/720,002 | 2022-04-13 | ||
| US17/720,002 US11730804B1 (en) | 2022-04-13 | 2022-04-13 | Compositions and methods for the prevention and treatment of rabies virus infection |
| PCT/US2023/065677 WO2023201263A1 (en) | 2022-04-13 | 2023-04-12 | Compositions and methods for the prevention and treatment of rabies virus infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025513827A JP2025513827A (ja) | 2025-04-30 |
| JP2025513827A5 true JP2025513827A5 (enExample) | 2026-04-17 |
Family
ID=87575492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024560232A Pending JP2025513827A (ja) | 2022-04-13 | 2023-04-12 | 狂犬病ウイルス感染症の予防及び治療のための組成物及び方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11730804B1 (enExample) |
| EP (1) | EP4508066A1 (enExample) |
| JP (1) | JP2025513827A (enExample) |
| KR (1) | KR20250023343A (enExample) |
| CN (1) | CN119487054A (enExample) |
| AU (1) | AU2023254835A1 (enExample) |
| CA (1) | CA3256261A1 (enExample) |
| CL (1) | CL2024003076A1 (enExample) |
| CO (1) | CO2024013755A2 (enExample) |
| CU (1) | CU20240033A7 (enExample) |
| DO (1) | DOP2024000204A (enExample) |
| IL (1) | IL316175A (enExample) |
| MX (1) | MX2024012693A (enExample) |
| PE (1) | PE20250795A1 (enExample) |
| TW (1) | TW202400800A (enExample) |
| WO (1) | WO2023201263A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2841047A1 (en) * | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic compositions and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6589533B1 (en) * | 1997-09-18 | 2003-07-08 | Research Development Foundation | Genetically-engineered alphaviruses, flaviviruses, and bunyaviruses with modified envelope transmembrane glycoproteins and altered host-range phenotype |
| CN1989250B (zh) * | 2004-05-18 | 2013-11-20 | 阿尔法瓦克斯公司 | Tc-83衍生的甲病毒属载体、颗粒和方法 |
| US11992526B2 (en) * | 2017-11-06 | 2024-05-28 | Intervet Inc. | Rabies virus vaccine |
-
2022
- 2022-04-13 US US17/720,002 patent/US11730804B1/en active Active
-
2023
- 2023-04-12 JP JP2024560232A patent/JP2025513827A/ja active Pending
- 2023-04-12 AU AU2023254835A patent/AU2023254835A1/en active Pending
- 2023-04-12 PE PE2024002214A patent/PE20250795A1/es unknown
- 2023-04-12 US US18/856,455 patent/US20250186574A1/en active Pending
- 2023-04-12 CN CN202380045492.3A patent/CN119487054A/zh active Pending
- 2023-04-12 KR KR1020247036825A patent/KR20250023343A/ko active Pending
- 2023-04-12 EP EP23789131.2A patent/EP4508066A1/en active Pending
- 2023-04-12 WO PCT/US2023/065677 patent/WO2023201263A1/en not_active Ceased
- 2023-04-12 CA CA3256261A patent/CA3256261A1/en active Pending
- 2023-04-12 CU CU2024000033A patent/CU20240033A7/es unknown
- 2023-04-12 IL IL316175A patent/IL316175A/en unknown
- 2023-04-13 TW TW112113755A patent/TW202400800A/zh unknown
-
2024
- 2024-10-11 CO CONC2024/0013755A patent/CO2024013755A2/es unknown
- 2024-10-11 DO DO2024000204A patent/DOP2024000204A/es unknown
- 2024-10-11 CL CL2024003076A patent/CL2024003076A1/es unknown
- 2024-10-11 MX MX2024012693A patent/MX2024012693A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7235235B2 (en) | Alphavirus RNA replicon systems | |
| CA2447450A1 (en) | Corona-virus-like particles comprising functionally deleted genomes | |
| US20050112752A1 (en) | Method for the purification of alphavirus replicon particles | |
| JP2018536433A5 (enExample) | ||
| JP2025184979A5 (enExample) | ||
| JP2002542827A5 (enExample) | ||
| JP2007509607A5 (enExample) | ||
| JP2024180560A5 (enExample) | ||
| JP2024510610A5 (enExample) | ||
| JP2023527791A5 (enExample) | ||
| WO2006037038B1 (en) | Optimized vaccines to provide protection against ebola and other viruses | |
| JP2025513827A5 (enExample) | ||
| JP2023536570A5 (enExample) | ||
| JP2023522154A5 (enExample) | ||
| CN113842453A (zh) | 一种抑制SARS-CoV-2的纳米捕集剂 | |
| Atkins et al. | Alphaviruses and their derived vectors as anti-tumor agents | |
| WO2003006654A2 (en) | Recombinant proteins of parapoxvirus ovis and pharmaceutical compositions therefrom | |
| CN111378629A (zh) | 一种仿生2019新型冠状病毒、其制备方法及应用 | |
| WO2024152852A1 (zh) | 表达il-7的sinv载体及其在制备抗肿瘤药物中的应用 | |
| WO2024114673A1 (zh) | 一种水泡性口炎病毒的致弱方法及致弱病毒株和应用 | |
| Kelly et al. | Potential of alphavirus vectors in the treatment of advanced solid tumors | |
| JP2024523329A5 (enExample) | ||
| JP2024511356A5 (enExample) | ||
| CN115975053A (zh) | 靶向新型冠状病毒的疫苗 | |
| JP2023529836A5 (enExample) |